Home > Search Clinical Trials > Cancer - Lung

IRB No. O25-227-1 (Dr. Omar Ibrahim, PI): A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer

The purpose of this study is to see how effective the injection of the radiation enhancer called JNJ-90301900 into tumor(s), before receiving concurrent chemoradiotherapy (cCRT) followed by immunotherapy (cIT) is, compared to receiving cCRT alone followed by cIT (without JNJ-90301900).